This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Daiichi Sankyo, Inc.
measure of the level of warfarin exposure, calculated as the total days of supply associated with warfarin prescription claims during the follow-up period
Reference
Casciano JP, et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. Journal of Managed Care Pharmacy 19: 302-16, No. 4, May 2013. Available from: URL: http://dx.doi.org/2013(19)4:302-316
Rights and permissions
About this article
Cite this article
Suboptimal warfarin use in AF significant economic burden. PharmacoEcon Outcomes News 679, 6 (2013). https://doi.org/10.1007/s40274-013-0433-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0433-3